Prospects for primary prevention of cervical cancer in developing countries

Salud Publica de Mexico

Volumn 45, Issue SUPPL. 3, 2003, Pages

  Franceschi, Silvia ^a   Clifford, Gary ^a   Plummer, Martyn ^a,b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NONE   (France)

Author keywords

Cervix neoplasms; Projection; Randomized controlled trials; Vaccination

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL TRIAL; CONDOM; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INDIA; INFECTION PREVENTION; MONITORING; REVIEW; SEXUALLY TRANSMITTED DISEASE; SOUTH KOREA; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0348050471     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36342003000900017     Document Type: Review

References (31)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Sherris J, Herdman C. Preventing cervical cancer in low-resource settings. Outlook 2000;18:1-8.
3. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001;79:954-962.
4. Wesley R, Sankaranarayanan R, Mathew B, Chandralekha B, Aysha Beegum A, Amma NS et al. Evaluation of visual inspection as a screening test for cervical cancer. Br J Cancer 1997;75:436-440.
5. Sankaranarayanan R, Wesley R, Somanathan T, Dhakad N, Shyamalakumary B, Amma NS et al. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer 1998;83:2150-2156.
6. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. IARC: Lyon, 1995;Vol. 64.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;18:12-19.
8. Herrero R, Hildesheim A, Bratti C, Sherman M, Hutchinson M, Morales J et al. A population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474.
9. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-420.
10. Franceschi S, Castellsagué X, Dal Maso L, Smith JS, Plummer M, Ngelangel C et al. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer 2002;86:705-711.
11. Molano M, Posso H, Weiderpass E, van den Brule AJC, Ronderos M, Franceschi S et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002;87:324-333.
12. Castellsagué X, Bosch FX, Muñoz N, Meijer C, Shah K, de Sanjosé S, Eluf-Neto J et al. Male circumcision, penile human papillomavirus infection and cervical cancer in female partners. N Engl J Med 2002;346:1105-1112.
13. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS et al. Role of parity and human papillomavirus in cervical cancer:The IARC multicentric case-control study. Lancet 2002;359:1093-1101.
14. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet 2002;359:1085-1092.
15. Plummer M, Herrero R, Franceschi S, Meijer CJLM, Snijders P, Bosch FX et al. Smoking and cervical cancer: Pooled analysis of are a multicentric case-control study. Cancer Causes R Control. In press.
16. Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer J Natl Cancer Inst. 2002;94:1604-1613.
17. th International Papillomavirus Conference; 2001;Florianopolis, Brazil. O-135.
18. Kols A, Sherris J. HPV Vaccines: Promise and challenges. Seattle (WA): PATH, 2000.
19. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;21:284-292.
20. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomaviruses in invasive cervical cancer worldwide: A meta-analysis. J Natl Cancer Inst Br J. Cancer 2003;88:63-73.
21. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A phase I study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001;183:1485-1493.
22. Koutsky LA, Wheeler Cm, Brown DR, Barr E, Alvarez FB, Chiacchierini LM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
23. Franceshi S. Strategies to reduce the risk of virus-related cancers. Ann Oncol 2000;11:1091-1096.
24. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Hepatitis viruses. IARC: Lyon, 1994;Vol. 59.
25. Gambia Hepatitis Study Group. The Gambia hepatitis intervention study. Cancer Res 1987;47:5782-5787.
26. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R et al. Hepatitis B vaccination in infancy in The Gambia: Protection against carriage at 9 years of age. Vaccine 1999;17:2946-2950.
27. Huang K, Lin S. Nationwide vaccination: A success story in Taiwan. Vaccine 2000;18(Suppl 1):S35-S38.
28. Beral V, Hermon C, Muñoz N, Devesa SS. Cervical cancer. Cancer surv 1994;19/20:265-285.
29. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. International Agency for Research on Cancer, Lyon: Vol. VII; IARC Scientific publications No 143. 1997.
30. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001;82:205-238.
31. Nardelli-Haefliger D, Wirthner D, Schiller J, Lowy DR, Hildesheim A, Ponci F. Specific antibody levels at the cervix during menstrual cycle of women vaccinated with human papillomavirus 16 virus like particles. J Natl Cancer Inst 2003;95:1128-1137.